Phospholine Iodide
echothiophate iodide 0.125% · ophthalmic solution
Antiglaucoma, Misc.
Approved uses
Elevated intraocular pressure
one drop of 0.125% twice a day, just before retiring and in the morning; a single dose per day or every other day has been used with satisfactory results
Added to maximal therapy, 75% of eyes dropped 20% or more, responders falling from about 30 to 17 mmHg.
Concomitant esotropia with a significant accommodative component
Diagnosis: one drop of 0.125% in both eyes on retiring for two or three weeks. Treatment: lowest frequency that gives satisfactory results; the schedule may be reduced to one drop every other day, and the maximum usually recommended dosage is one drop once a day
Contraindications
- Active uveal inflammation.
- Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block.
- Hypersensitivity to the active or inactive ingredients.
Ophthalmic solution, 0.125% (6.25 mg package supplied with diluent and dropper for 5 mL of eyedrops)
Long-acting cholinesterase inhibitor that enhances endogenously liberated acetylcholine at the iris, ciliary muscle, and other parasympathetically innervated ocular structures, causing miosis, increased facility of aqueous outflow, a fall in IOP, and potentiation of accommodation. Topical therapy depresses both plasma and erythrocyte cholinesterase in most patients after a few weeks.
Warnings & Precautions
- Respiratory or cardiovascular collapse: Succinylcholine should be given only with great caution, if at all, before or during general anesthesia to a patient receiving anticholinesterase medication.
- Adverse additive effects: Caution when treating elevated IOP in a patient concurrently on systemic anticholinesterase medication, because of possible adverse additive effects.
- Additive systemic effects: Patients exposed to carbamate- or organophosphate-type insecticides and pesticides should be warned of the additive systemic effects possible from absorption through the respiratory tract or skin; respiratory masks, frequent washing, and clothing changes may be advisable during exposure.
- Muscle weakness or respiratory difficulties: Temporary discontinuance is necessary if salivation, urinary incontinence, diarrhea, profuse sweating, muscle weakness, or respiratory difficulties occur.
- Cardiac irregularities: Discontinue if they occur.
- Vagotonic effects: Use with caution, if at all, in marked vagotonia, bronchial asthma, spastic gastrointestinal disturbance, peptic ulcer, pronounced bradycardia and hypotension, recent myocardial infarction, epilepsy, parkinsonism, and other disorders that may respond adversely to vagotonic effects.
- Retinal detachment: Use with caution where there is a prior history of retinal detachment.
- Drainage and skin absorption: Digital compression of the nasolacrimal ducts for a minute or two following instillation to minimize drainage into the nasal chamber is recommended. To prevent possible skin absorption, hands should be washed following instillation.
- Regular examinations: Regular examinations are advisable when the drug is being prescribed for the treatment of accommodative esotropia.
Common Side Effects
Stinging, burning, lacrimation, lid muscle twitching, conjunctival and ciliary redness, browache, and induced myopia with visual blurring may occur, and activation of latent iritis or uveitis may occur. Iris cysts may form and, if treatment is continued, may enlarge and obscure vision; they are more frequent in children, usually shrink when the drug is stopped or the frequency reduced, and rarely may rupture or break free into the aqueous. Prolonged use may cause conjunctival thickening and obstruction of nasolacrimal canals, and lens opacities have been reported. A paradoxical increase in IOP may follow instillation and may be alleviated by a sympathomimetic mydriatic such as phenylephrine. Retinal detachment has been reported in a few adults without a previous history, although the relationship to the drug has not been established. Systemic reactions include cardiac irregularities.
Pregnancy: Animal reproduction studies have not been conducted and fetal harm potential is unknown; give only if clearly needed.
Lactation: Because of the potential for serious adverse reactions in a nursing infant, decide whether to stop nursing or stop the drug, weighing its importance to the mother.
Safety and effectiveness established; iris cysts occur more frequently in children.